Hecht Beth 4

What Happened
Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (ticker: XERS), sold 16,667 shares in an open-market transaction on June 1, 2026. The reported weighted-average sale price was $6.06 per share for total proceeds of about $100,982. The shares were sold in multiple transactions at prices ranging from $5.98 to $6.18.

Key Details

• Transaction date: 2026-06-01 (filed on 2026-06-02). Filing appears timely (within required Form 4 window).
• Transaction type: Sale (S) — open market.
• Shares sold: 16,667; weighted average price: $6.06; total proceeds ≈ $100,982.
• Price range: $5.98 to $6.18 (sold in multiple trades; reporter can provide per-trade details on request).
• Footnotes: Trade was effected under a Rule 10b5-1 trading plan (pre‑arranged trading plan).
• Shares owned after transaction: Not specified in the provided filing.

Context
Sales under Rule 10b5-1 plans are pre-scheduled and common for insiders managing diversification or liquidity needs; they do not necessarily indicate a change in sentiment about the company. For retail investors, purchases typically carry more informational weight than routine sales, but tracking insider activity over time can still be useful.